Some Notable Presentations Over The Past Year:
1. Dr. Ihor Gussak chaired the automated cardiac safety solution segment of the Cardiac Safety Vendor Workshop in London. The segment featured a Who’s Who in the cardiac safety industry focusing on the market adoption of the automated solution. Here, FDA representatives reinforced their support of the use of automated solutions in TQT studies.
2. Dr. Sam George, Senior Medical Consultant, joined a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in October.
3. They presented two abstracts and discussed new clinical data from analytical and clinical applications of their proprietary platform technology at The Heart Rhythm Society (HRS) 30th Annual Scientific Sessions.
4. At the DIA Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development - Optimizing Drug Development Conference, co-sponsored by the FDA and the HRS, they presented their technology and clinical validation results along with their primary automatic solution competitors.
5. NewCardio, Inc. Presented at the 2nd Annual LD MICRO Conference in Los Angeles. LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space.
6. NewCardio, Inc. to Present at the One Med Forum 2010 Emerging Company Finance Conference. The One Med Place Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners.
7. NewCardio's Chief Medical Officer, Dr. Ihor Gussak, presented at the Prestigious Cardiac Electrophysiology Conference in Tokyo. The J-IVFS is one of the most prestigious Cardiac Electrophysiology events in the world, covering areas of particular focus in Japan where idiopathic sudden cardiac arrest is endemic and very problematic.
8. The Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF).
9. Two of NWCI’s most recent medical and technical submissions have been accepted for presentation at the prestigious 15th Annual World Congress on Heart Disease to be held in Vancouver BC. The Company will present data from both the advanced coronary artery disease (CAD) and atrial fibrillation (AF) clinical studies, with additional information from ongoing CardioBip™ clinical studies. The data supports CardioBip’s suitability for long-term monitoring of patients with CAD and AF.
10. NWCI unveiled its patented CardioBip™ technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society (HRS) 31st Annual Scientific Sessions.
11. Five of its most recent medical and technical submissions have been accepted for publication in prominent peer-reviewed medical journals. These publications will present important clinical data supporting the accuracy and effectiveness of its CardioBip™ and Cardio3KG™ products.
12. Two of its recent medical and technical submissions have been accepted for presentation at the 32nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society conference. The two papers: “Wireless Transmission of Reconstructed 12-Lead ECGs in the Remote Monitoring of Atrial Fibrillation” and “Wireless Remote Monitoring of Myocardial Ischemia Using Reconstructed 12-Lead ECGs” will be presented during the conference to be held August 31st through September 4th, 2010, in Buenos Aires, Argentina.
